Zacks Investment Research | Jul 16, 2017 09:26PM ET
Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson & Johnson (NYSE:JNJ) reporting second quarter results tomorrow before the market opens. Swiss pharma giant, Novartis (NYSE:NVS) , which was in the news recently related to a favorable FDA advisory panel recommendation for its CAR-T cell therapy, will also be reporting second quarter results tomorrow.
As of Jul 14, 2017, about 30 S&P 500 members or 9.3% of the index’s total market capitalization have reported results. A look at our Earnings ESP for the second quarter.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) : Canada-based specialty pharma company, Valeant, has been in the headlines mainly due to the drug pricing controversy and its relationship with Philidor. The Zacks Rank #5 stock, which missed earnings expectations in two of the last four quarters and revenue expectations in the first quarter of 2017, has a negative earnings ESP of 9.38% for the second quarter of 2017. The company, which has been working on simplifying its operating model and reducing debt, will be reporting results on Aug 8. Earnings estimates for 2017 are down 0.5% over the last 30 days.
Flexion Therapeutics, Inc. (NASDAQ:FLXN) : Burlington, MA-based Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis. The Zacks Rank #4 stock, which missed loss estimates in two of the last four quarters, has a negative earnings ESP of 7.5% for the second quarter of 2017. Loss estimates for the June quarter and 2017 are up 1.3% and 0.6%, respectively, over the last 7 days. Flexion is expected to report second quarter results on Aug 2.
Ignyta, Inc. (NASDAQ:RXDX) : San Diego, CA-based Ignyta is focused on precision medicine in oncology. The Zacks Rank #4 stock, which posted a wider-than-expected loss in two of the last three quarters, has a negative earnings ESP of 13.12% for the second quarter of 2017. Loss estimates for the June quarter and 2017 are up 17.3% and 1.9%, respectively, over the last 30 days. Ignyta is expected to report second quarter results on Aug 8.
Anika Therapeutics, Inc. (NASDAQ:ANIK) : Bedford, MA-based Anika is a global, integrated orthopedic medicines company. The Zacks Rank #5 stock, which missed first quarter earnings estimates, has a negative earnings ESP of 4.55% for the second quarter of 2017. While earnings estimates for the June quarter are down 10.2% over the last 30 days, full year 2017 estimates are down 5.6% during this period. Anika will be reporting second quarter results on Jul 26. Year-to-date, the company’s shares are down 5.8%, underperforming the Zacks-categorized Medical-Biomedical/Genetics industry which is up almost 9%.
While you can uncover the best stocks to buy or sell before they're reported with our Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.